Lilly at the EASD Annual Meeting in Milan (Elizabeth Cairns for Endpoints News)
Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
MILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP.
Data revealed Wednesday show that Lilly’s …